Covid-19 living Data

Pharmacologic treatments for covid-19 patients

Hydroxychloroquine+Ribavirin vs Standard care

This comparison will not be updated. Last search date 28 Feb, 2022.

Hospitalized patients

Forest plots
(last update: 2022-04-12)

Summary of findings
(last update: 2022-04-27)

Patient or population: COVID-19 patients
Setting: Worldwide
Intervention: Hydroxychloroquine+Ribavirin
Comparison: Standard care

Outcome	Relative effect (95% CI)	Absolute effect (95% CI)¹		Certainty of the Evidence (GRADE)
Clinical improvement D28	Outcome not yet measured or reported
Clinical improvement D60	Outcome not yet measured or reported
WHO progression score (level 7 or above) D28	Outcome not yet measured or reported
WHO progression score (level 7 or above) D60	Outcome not yet measured or reported
All-cause mortality D28	RR: 0.52 (0.15 - 1.84)	65 fewer per 1000 (from 116 fewer to 115 more)		Very low certainty Reasons to downgrade Risk of bias: Serious Risk of bias downgraded by 1 level: some concerns regarding a deviation from intended intervention and missing data Inconsistency: Not serious Indirectness: Serious studies from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
2 trials Panda PK 2021; Panda PK, 2021 (2) 87 participants		Hydroxychloroquine+Ribavirin 71 per 1,000 (20 - 251)	Standard care 136 per 1,000
All-cause mortality D60	Outcome not yet measured or reported
Viral negative conversion D7	Outcome not yet measured or reported
Adverse events	Outcome not yet measured or reported
Serious adverse events	Outcome not yet measured or reported

¹The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)

CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

To access all information :

click here for Hospitalized patients

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=426

Back to your research


CTRI/2020/06/025575 Panda PK, Clin Pharmacol, 2021 Full text Full text Commentary Commentary	No specific funding	Hydroxychloroquine+Ribavirin Lopinavir+Ritonavir+Ribavirin Hydroxychloroquine+Ribavirin	Standard care Standard care Lopinavir+Ritonavir+Ribavirin	RCT	Patients with confirmed COVID-19 (severe-critical) admitted to a single center in India.	N=71	Some concerns Details	Full description
CTRI/2020/06/025575 Panda PK(2), Clin Pharmacol, 2021 Full text Full text Commentary Commentary	No specific funding	Hydroxychloroquine+Ribavirin	Standard care	RCT	Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in India.	N=40	Some concerns Details	Full description

Trial

Funding

Comparisons

Design

Participants

Sample size

Overall risk
of bias
Highest assessment

Full description

Treatment 1

Treatment 2

CTRI/2020/06/025575
Panda PK, Clin Pharmacol, 2021
Full text
Full text
Commentary
Commentary

No specific funding

Hydroxychloroquine+Ribavirin

Lopinavir+Ritonavir+Ribavirin

Hydroxychloroquine+Ribavirin

Standard care

Lopinavir+Ritonavir+Ribavirin

RCT

Patients with confirmed COVID-19 (severe-critical) admitted to a single center in India.

N=71

Some concerns
Details

Full description

CTRI/2020/06/025575
Panda PK(2), Clin Pharmacol, 2021
Full text
Full text
Commentary
Commentary

No specific funding

Hydroxychloroquine+Ribavirin

Standard care

RCT

Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in India.

N=40

Some concerns
Details

Full description